Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study

BACKGROUND: The COVID-19 pandemic disrupted Alzheimer disease randomized clinical trials (RCTs), forcing investigators to make changes in the conduct of such trials while endeavoring to maintain their validity. Changing ongoing RCTs carries risks for biases and threats to validity. To understand the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Lon S., Qiu, Yuqi, Thomas, Ronald G., Evans, Carol, Jacobs, Diane M., Jin, Shelia, Kaye, Jeffrey A., LaCroix, Andrea Z., Messer, Karen, Salmon, David P., Sano, Mary, Schafer, Kimberly, Feldman, Howard H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686345/
https://www.ncbi.nlm.nih.gov/pubmed/34930444
http://dx.doi.org/10.1186/s13195-021-00938-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686345/
https://www.ncbi.nlm.nih.gov/pubmed/34930444
http://dx.doi.org/10.1186/s13195-021-00938-w

Ejemplares similares